NCT06487000

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Phase 2 Clinical Trial to Evaluate Efficacy and Safety of EC-18 in Moderate to Severe Atopic Dermatitis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Enzychem Lifesciences Corporation · Industry
• Sex: All
• Age: 19 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis

Detailed description

This study will utilize a randomized, double blind, placebo-controlled, parallel-group, multi-Center design. The Experimental group 1 will receive 1000mg of EC-18\[2 capsules of EC-18 500mg, 2 capsules of placebo\]. The experimental group 2 will receive 2000mg of EC-18 \[4 capsules of EC-18\]. The placebo group will receive 4 capsules of placebo. The time frame of this clinical trial will consist 16 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	EC-18	oral administration, QD
DRUG	Placebo EC-18	oral administration, QD

Timeline

• Start date: 2025-05-01
• Primary completion: 2026-10-01
• Completion: 2026-12-01
• First posted: 2024-07-05
• Last updated: 2024-11-08